The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:
* What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease? * What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.
Age 18-45 years;
Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
Voluntary participation with signed informed consent.
Heart transplant recipients;
Severe systemic comorbidities with life expectancy <1 year;
Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).
Eligible participants are CAD patients aged 18-45 years confirmed by coronary angiography or other imaging modalities, including those with stable/unstable angina or myocardial infarction.
Cohort
Prospective
Not listed
MACCE, defined as a composite of cardiac death, MI, ischemic stroke, and repeat revascularization
Sensitivity for 2-year MACCE prediction
For the validation cohort
Specificity for 2-year MACCE prediction
For the validation cohort
Incidence of death (cardiovascular, noncardiovascular, and undetermined) at 1 m, 6 m, 1 y and 2 y
For the development cohort
Incidence of MI (target vessel related and non-target vessel related or Culprit and non-culprit lesion-related) at 1 m, 6 m, 1 y and 2 y
For the development cohort
Incidence of all revascularizations (ischemia driven vs. non-ischemia driven; Target vs. non-target vessel; Culprit vs. non-culprit lesion) at 1 m, 6 m, 1 y and 2 y
For the development cohort
Incidence of definite or probable stent thrombosis during the acute, subacute, late, and very late phase according to the ARC-2 criteria
For the development cohort
Click on the lead sponsor to view all of their trials.
